"When you write a script for TB-500, what form do you think your patients are getting? Does anyone know? I certainly don't."
That was a physician, on the record, at the FDA's own advisory meeting on July 23 and 24, 2026, describing the exact compound the committee was about to advance. He didn't know what would end up in the vial. Neither did the panel that voted yes anyway.
Your feed told you the FDA approved peptides. It did not.
Here is the boring, precise truth. A non-binding advisory committee — the Pharmacy Compounding Advisory Committee, or PCAC — recommended that six bulk substances be added to a list traditional compounding pharmacies may draw from when filling an individual prescription.
That is a pharmacy-access question. It is not a finding that anything is safe or effective.
Nothing is legal today that was not legal on July 22. Before any of these six could be lawfully compounded, the FDA must accept the recommendation and then complete formal notice-and-comment rulemaking, a process legal analysts expect to run into 2027 or beyond.
So sit with the gap between "FDA approved peptides" and what happened: an outside panel suggested that pharmacies might one day be allowed to mix these compounds for patients holding a script. That is the whole event.
An outside panel suggested that pharmacies might one day be allowed to mix these compounds for patients holding a script. That is the whole event.
Now the part almost nobody shared.
The FDA's own career scientists reviewed each of the seven nominated peptides for the specific uses proposed — BPC-157 for ulcerative colitis, KPV for wound healing, TB-500 for wound healing, MOTS-c for obesity and osteoporosis — and reportedly recommended against all seven. Unanimously. They cited a lack of clinical data, batch-to-batch inconsistency, and the risk of harmful immune reactions.
They were overruled.
BPC-157, KPV, and TB-500 each advanced 8 to 6 with one abstention. And here is the detail that reframes everything: six of the eight members recently appointed to the panel run clinics that offer peptides. For BPC-157, KPV, and TB-500, all eight new appointees voted yes.
The votes weren't cast in the language of evidence. They were cast in the language of movement politics.
Dr. Haleem Mohammed, chief medical officer at a men's health clinic that offers peptides, said he voted yes "for patient safety, you know, the greater good and medical freedom." Another member said his yes was "to put this decision back into the hands of the patient, the physician and the pharmacist."
The dominant argument was harm reduction: people are already buying these compounds from overseas "research use only" sellers, so a licensed pharmacy is safer. Mohammed said what kept him up at night was "pushing it to the gray market."
This is where you need to see what was quietly swapped out.
The regulatory standard for adding a substance to the 503A list is physical and chemical characterization, safety, and evidence of effectiveness. "People are buying it anyway" is not on that list. It is not an evaluation criterion at all.
Georgetown pharmacologist Adriane Fugh-Berman put the substitution in a sentence during public testimony: "Would the government endorse manufacturing heroin because it's cleaner than what is sold on the street? Just because a market is large doesn't mean that a product should be legalized. It means that a product should be studied."
That is the actual precedent being set. Not that peptides are uniquely dangerous — that market size was allowed to stand in for evidence.
And the evidence gap is not close. NYU Langone's Dr. Rachel Pessah-Pollack reportedly noted that BPC-157 has been tested in roughly 30 humans. The GLP-1s — peptides that went through the real process — were tested in hundreds of thousands.
"Anecdotes are not evidence," she said.
The problem ran deeper than thin data. It ran to identity. "We've never faced a problem of, 'What is it?'" FDA official Russell Wesdyk told the panel — because there was no universally accepted chemical formula for each peptide. The briefing materials noted multiple forms, and in some cases multiple published amino acid sequences, for the same substance.
The panel was voting to authorize the compounding of things it could not fully define.
Now the sharpest point, the one that gets lost in the medical-freedom shouting.
Supporters kept saying inclusion would create a chance to study these compounds further, that the evidence would catch up. The attorneys at Mintz explain, in flat structural terms, why that is backwards.
Authorizing a compound to be sold commercially "removes incentives for drug developers to formally study these peptides in clinical trials or seek FDA marketing approval." Why fund an expensive trial for a molecule you can already sell without one?
"The evidence will catch up" is not merely optimistic. It is structurally false. Commercial access is the thing that kills the trial.
Here is the honest counterargument, and it deserves better than a wave of the hand. Some argue the plural of anecdote is data — that when thousands of patients and clinicians independently report the same result, the accumulation becomes hard to dismiss.
There is something to this. A randomized trial is itself built from individual outcomes; the group average is just those personal results, organized. An anecdote is an observation. Data are observations collected in a way that lets you compare them.
So the plural of anecdote can be data. It just isn't necessarily good data — because anecdotes carry the expectancy effect, regression to the mean, and selection bias, none of which cancel out no matter how many you stack.
But there is a second problem specific to compounded peptides, and it is fatal to the "we'll learn as we go" hope.
For anecdotes to accumulate into anything learnable, the thing being observed has to be the same thing each time. It isn't. The ingredients are uncharacterized and non-standardized, with multiple forms and multiple sequences in circulation.
As Mintz puts it, that makes "outcome comparisons from one setting to another extremely difficult." When you can't confirm that two patients received the same molecule, you can't pool their experiences into evidence. You just have noise, at scale.
So the accumulation argument collapses precisely where it needs to hold. You need standardization to learn from repetition, and commercial compounding delivers the opposite.
What does this mean if peptides are on your radar?
A spot on a list is not a stamp. Adding these compounds does not make them supplements on a shelf, and it does not mean the FDA declared anything safe or effective. It opens a narrow, prescription-gated path — one that still skips the ongoing side-effect tracking and safety labeling that come with an approved drug.
The marketing is legally constrained, and this is worth knowing before you read the ad copy. Federal and state law require "competent and reliable scientific evidence" for health claims. Because that evidence does not exist here, "clinically proven" — and even "clinically tested" — would be off-limits.
If someone selling you a peptide uses those words, they are not describing the science. They are breaking the rule.
The honest evidence level, the one the public record now documents in detail, remains preclinical-to-anecdotal. That did not change on July 24. If anything, the vote pushed the day the evidence improves further away, by removing the reason anyone would ever produce it.
A list is not a verdict. It is a shelf. What goes on it still has to be studied — and this vote made that less likely, not more.